Page 5,743«..1020..5,7425,7435,7445,745..5,7505,760..»

Biogen to Buy Elan Stake in MS Drug Tysabri for $3.25 Billion

Posted: Published on February 7th, 2013

By Dow Jones Business News, February 06, 2013, 10:45:00 AM EDT --Biogen to acquire full control of blockbuster multiple-sclerosis drug Tysabri --Tysabri is seen as highly effective but also carries risk of fatal brain infection --Amgen to pay Elan royalties of between 18% and 25% of Tysabri sales Biogen Idec Inc. ( BIIB ) agreed to buy partner Elan Corp.'s (ELN, DRX.DB) interest in Tysabri for $3.25 billion, giving it full control of the blockbuster multiple-sclerosis drug. Biogen is betting that regulators will approve expanded use of the drug despite past safety concerns and help to bolster the company's already strong position in the lucrative MS market. The deal also carries risks. Though Tysabri is thought to be highly effective, it also can cause a fatal brain infection in certain patients, which has limited its use. In addition, new MS therapies are expected to launch soon that could steal its market share, including a new Biogen drug that is pending regulatory approval. "We believe in Tysabri," Chief Executive George Scangos said. "It's an important therapy for MS patients and an important asset for us." Investors applauded the deal as Biogen shares rose 5.8% to $166.47. For Elan, the deal provides … Continue reading

Posted in MS Treatment | Comments Off on Biogen to Buy Elan Stake in MS Drug Tysabri for $3.25 Billion

Biogen's purchase of MS drug ends rocky partnership with Elan

Posted: Published on February 7th, 2013

BOSTON (Reuters) - Biogen Idec Inc's agreement to buy Elan Corp Plc's interest in the multiple sclerosis drug Tysabri gives Biogen full control of a product that is poised for further growth and ends a long partnership that has often been contentious. Analysts have speculated for several years that Biogen could acquire Elan to take control of Tysabri. The current agreement, under which Biogen will pay Elan $3.25 billion in cash plus royalties, gives Biogen the asset it is most interested in while leaving Elan with money to spend on acquisitions and to develop its pipeline of experimental drugs. "With this deal Biogen does not have to deal with Elan's pipeline baggage," said David Ferreiro, an analyst at Oppenheimer & Co. Still, analysts expressed some surprise that Biogen has chosen this moment to double down on Tysabri. The company is poised to launch a new MS drug, BG-12, at the end of March. The drug, if approved, will be sold under the brand name Tecfidera. It is expected by many investors to become the leading treatment for the disease but is set to lose patent protection in the mid to late 2020s. "By that point, BG-12 could be the dominant … Continue reading

Posted in MS Treatment | Comments Off on Biogen's purchase of MS drug ends rocky partnership with Elan

week 108 1-2-13.wmv – Video

Posted: Published on February 7th, 2013

week 108 1-2-13.wmv week 108 update on (HRT) hormone replacement therapy. my blogg sumthingangels.blogspot.com donate at http://www.giveforward.com By: sumthingangelsvlg … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on week 108 1-2-13.wmv – Video

Acidhedz Discussion Zone ep 2 – Genetic Manipulation – Video

Posted: Published on February 7th, 2013

Acidhedz Discussion Zone ep 2 - Genetic Manipulation The notion of manipulating our DNA, our genes. The very building blocks of what, and who, we are. Stem Cell research. Seeking Perfection? Super humans? There are many issues that the idea of genetic manipulation brings up. Let's discuss them. acidbathproductions.biz By: Ryan Murphy … Continue reading

Posted in Stem Cell Research | Comments Off on Acidhedz Discussion Zone ep 2 – Genetic Manipulation – Video

New light shed on reprogramming mature cells to pluripotency, to divide and differentiate into specialized cell types

Posted: Published on February 7th, 2013

Feb. 6, 2013 Mature cells can be reprogrammed to pluripotency and thus regain the ability to divide and differentiate into specialized cell types. Although these so-called induced pluripotent stem cells (iPS cells) represent a milestone in stem cell research, many of the biochemical processes that underlie reprogramming are still not understood. Scientists from the EMBL Hamburg and from the Max Planck Institute for Molecular Biomedicine in Mnster, Germany now shed new light on this process. In a study published February 6 in Nature Cell Biology, the scientists describe important details about the structure of the transcription factor Oct4, known to play a crucial role in the reprogramming of terminally differentiated cells. The study broadens the knowledge about the reprogramming of cells and may pave the way for medical applications in the field of regenerative medicine and drug discovery. The transcription factor Oct4 is a protein that binds to DNA and controls the genes involved in reprogramming the cells. The team at EMBL Hamburg has now been able to resolve the crystal structure of Oct4 using high-intensity X-ray beams. In particular, their analysis focused on a previously unexplored linker sequence between two DNA binding elements of the protein. "The uniqueness of … Continue reading

Posted in Stem Cell Research | Comments Off on New light shed on reprogramming mature cells to pluripotency, to divide and differentiate into specialized cell types

Genetic screening in Metro Vancouver helps target lung cancer treatment

Posted: Published on February 7th, 2013

Asian women with late-stage lung cancer in Metro Vancouver are now routinely tested for a genetic mutation that can improve their treatment. Its a made-in-B.C. adaptation of international genetic research that has found a high proportion of Asian women with lung cancer have never smoked. They carry a particular genetic makeup that drives tumour growth yet also responds to a line of drugs called tyrosine kinase inhibitors, or TKIs. The treatment wont eradicate cancer, but can prolong lives, said Dr. Barbara Melosky, a researcher at the BC Cancer Agency and professor of medicine at the University of British Columbia. People have been talking about targeted therapy for 10 years, but we actually found one that works very well with lung cancer. Although we cannot cure these patients, many of them live years, rather than months. About 10 to 20 per cent of all lung cancer patients carry a mutated epidermal growth factor receptor gene that speeds tumour growth. That number rises to about 40 per cent among all East Asians with non-small-cell lung cancer, the most common type. Among non-smoking East Asian women from China, Japan, Taiwan and Korea, it rises to between 60 and 80 per cent. There were … Continue reading

Comments Off on Genetic screening in Metro Vancouver helps target lung cancer treatment

Study finds genetic basis of aortic valve disease, may point to possible therapy

Posted: Published on February 7th, 2013

TORONTO - A large international study has identified a gene mutation that increases the risk of developing a common and potentially fatal condition called aortic valve disease. The work pinpoints a mutation on a gene responsible for the production of a type of cholesterol known as lipoprotein(a) or Lp(a). The lead author, Dr. George Thanassoulis of McGill University in Montreal, says the mutation is found in about 13 per cent of people of European descent. It occurs to a lesser degree in people of African-American and Hispanic ethnicity, but is barely seen in people of Chinese-American ancestry. Thanassoulis says researchers were able to show that the mutation was the number one genetic risk factor for the disease, and that it was the circulating Lp(a) in the blood that was causing the valve disease in the people studied. About a million people in North America suffer from aortic stenosis, which is the hardening of the valve through which blood leaves the heart. People with the condition develop shortness of breath and angina, and can go on to have heart attacks. There is currently no remedy, except surgery to replace the valve. But by the time the condition is spotted, patients are … Continue reading

Comments Off on Study finds genetic basis of aortic valve disease, may point to possible therapy

Study finds genetic cause for common heart ailment

Posted: Published on February 7th, 2013

A genetic variation doubles the risk of developing calcium deposits in the heart, a common condition that, in severe cases, can narrow or block the aorta, according to a study published Wednesday. The genetic variation, found in seven percent of the population, provides important clues about how to treat the disease, researchers said in the study published in the New England Journal of Medicine. "This is an important step forward in understanding the biology of the development of aortic stenosis," said senior author Wendy Post, from the Johns Hopkins University School of Medicine. She added that the latest findings could lead to the development of targeted medications to slow the progression of the disease, which can cause chest pain and shortness of breath, and can in some cases require surgery. The gene in question is involved in the production of a type of cholesterol particle called lipoprotein (a), which circulates in the blood. "Increased levels of lipoprotein (a) have been previously associated with aortic valve disease. However, prior studies could not differentiate whether it was simply a marker or a causal factor," said lead author Catherine Campbell, of Kaiser Permanente. "Our results provide the first evidence for a causal relationship," … Continue reading

Comments Off on Study finds genetic cause for common heart ailment

Genetic cause for common heart ailment

Posted: Published on February 7th, 2013

A GENETIC variation doubles the risk of developing calcium deposits in the heart, a common condition that, in severe cases, can narrow or block the aorta. The genetic variation, found in seven per cent of the population, provides important clues about how to treat the disease, researchers said in a study published on Wednesday in the New England Journal of Medicine. "This is an important step forward in understanding the biology of the development of aortic stenosis," said senior author Wendy Post, from the US Johns Hopkins University School of Medicine. She added that the latest findings could lead to the development of targeted medications to slow the progression of the disease, which can cause chest pain and shortness of breath, and can in some cases require surgery. The gene in question is involved in the production of a type of cholesterol particle called lipoprotein (a), which circulates in the blood. "Increased levels of lipoprotein (a) have been previously associated with aortic valve disease. However, prior studies could not differentiate whether it was simply a marker or a causal factor," said lead author Catherine Campbell, of Kaiser Permanente. "Our results provide the first evidence for a causal relationship," she added. … Continue reading

Comments Off on Genetic cause for common heart ailment

Genetic variation doubles risk of aortic valve calcification

Posted: Published on February 7th, 2013

Feb. 6, 2013 Researchers have found a genetic variant that doubles the likelihood that people will have calcium deposits on their aortic valve. Such calcification, if it becomes severe, can cause narrowing or a blockage of the aortic valve, a condition called aortic stenosis. The study is the first large-scale, genome-wide association study to uncover a genetic link to aortic valve calcification. An article detailing the findings is published in the February 7, 2013 issue of The New England Journal of Medicine. The study's lead investigators -- from Johns Hopkins, Harvard University, McGill University, the University of Iceland and the National Institutes of Health -- found that having a genetic variant in the LPA gene, which codes for a type of cholesterol particle called lipoprotein (a), also increases the risk of developing aortic stenosis by more than 50 percent. The researchers say their findings not only help explain why heart valve calcification may run in families, they could also lead to the development of targeted medications that might slow the progression of the disease. Statin medications, which reduce common forms of cholesterol that can clog blood vessels, have not been shown to reduce aortic valve calcification. "This is an important … Continue reading

Comments Off on Genetic variation doubles risk of aortic valve calcification

Page 5,743«..1020..5,7425,7435,7445,745..5,7505,760..»